CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
24 juin 2024 07h00 HE
|
CytoSorbents
Taiwan FDA approval of CytoSorb brings powerful blood purification therapy to critically ill and cardiac surgery patients in the country
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
13 juin 2024 07h00 HE
|
CytoSorbents
The launch of the PuriFi hemoperfusion machine is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification therapy
CytoSorbents Reports First Quarter 2024 Results
09 mai 2024 16h17 HE
|
CytoSorbents
CytoSorbents Reports First Quarter 2024 Results
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02 mai 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
26 avr. 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
14 mars 2024 16h39 HE
|
CytoSorbents
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
06 mars 2024 07h00 HE
|
CytoSorbents
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
08 févr. 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
17 janv. 2024 07h15 HE
|
CytoSorbents
CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
08 janv. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cytosorbents Corporation...